Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

Core Viewpoint - Aardvark Therapeutics has established a new wholly-owned subsidiary, Ardia Therapeutics, to focus on developing a dermatology pipeline, particularly the lead asset DIA-615, aimed at treating inflammatory skin diseases like psoriasis [1][4]. Group 1: Company Overview - Aardvark Therapeutics is a clinical-stage biopharmaceutical company that develops small-molecule therapeutics targeting metabolic diseases and hunger-related conditions, with its lead compound ARD-101 in Phase 3 clinical development for Prader-Willi Syndrome [5]. - The newly formed Ardia Therapeutics will concentrate on DIA-615, a topical treatment designed to target inflammatory cells in the skin, utilizing a mechanism that involves specific G protein-coupled receptors [4]. Group 2: Leadership and Management - Bryan Jones, Ph.D., has been appointed as the CEO of Ardia, transitioning from his previous role as COO at Aardvark, bringing over 30 years of experience in biotech and specialty pharmaceuticals [2][3]. - Dr. Jones has a notable background, having held significant positions in various biotech companies and successfully leading multiple development programs throughout his career [3]. Group 3: Product Development - DIA-615 is positioned as a clinic-ready topical drug aimed at treating various inflammatory skin diseases, including psoriasis, by downregulating stressed endoplasmic reticulum in inflammatory cells [4]. - The development of DIA-615 is expected to address serious unmet needs in the treatment of severe skin diseases, with the potential for significant impact on patient care [2][3].